IGV-001 Phase 3 initiation
Imvax reports FDA alignment on elements of a planned Phase 3 trial in unmethylated-MGMT newly diagnosed GBM. Alignment is not itself trial activation or proof of efficacy.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Exact protocol and funding readiness require refresh; the reported Phase 2b subgroup P value must not be recast as a successful prespecified pivotal result.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Planned Phase 3 — first-dose date unconfirmed
Company context
Opened Vaxcyte 2026 DEF 14A. John Furey biography explicitly calls Imvax Inc. a privately held clinical-stage biotechnology company. Positive SEC-filed disclosure of director affiliation, not independent October 31 registry proof.
Potential outcome market
Will the first participant be dosed in the designated IGV-001 Phase 3 uMGMT glioblastoma trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.